HomeCompareGGSM vs PFE

GGSM vs PFE: Dividend Comparison 2026

GGSM yields 250000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GGSM wins by $4.567699004441311e+30M in total portfolio value
10 years
GGSM
GGSM
● Live price
250000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.567699004441311e+30M
Annual income
$4,564,107,688,187,857,300,000,000,000,000,000,000.00
Full GGSM calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — GGSM vs PFE

📍 GGSM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGGSMPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GGSM + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GGSM pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GGSM
Annual income on $10K today (after 15% tax)
$21,250,000.00/yr
After 10yr DRIP, annual income (after tax)
$3,879,491,534,959,678,500,000,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, GGSM beats the other by $3,879,491,534,959,678,500,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GGSM + PFE for your $10,000?

GGSM: 50%PFE: 50%
100% PFE50/50100% GGSM
Portfolio after 10yr
$2.2838495022206556e+30M
Annual income
$2,282,053,844,093,928,700,000,000,000,000,000,000.00/yr
Blended yield
99.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

GGSM
No analyst data
Altman Z
0.0
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GGSM buys
0
PFE buys
0
PoliticianChamberTickerTypeAmountDate
Thomas R. Carper🏛 Senate$GGSM▼ Sell$1,001 - $15,0002021-02-12
Thomas R. Carper🏛 Senate$GGSM▼ Sell$1,001 - $15,0002021-02-12
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGGSMPFE
Forward yield250000.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$4.567699004441311e+30M$49.6K
Annual income after 10y$4,564,107,688,187,857,300,000,000,000,000,000,000.00$26,258.71
Total dividends collected$4.567463897060879e+30M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GGSM vs PFE ($10,000, DRIP)

YearGGSM PortfolioGGSM Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$25,010,700$25,000,000.00$9,153$693.39+$25.00MGGSM
2$58,462,976,402$58,436,214,953.27$8,593$849.25+$58462.97MGGSM
3$127,722,124,784,416$127,659,569,399,665.92$8,336$1,066.78+$127722124.78MGGSM
4$260,784,910,907,288,130$260,648,248,233,768,800.00$8,437$1,384.80+$260784910907.28MGGSM
5$497,657,939,618,196,950,000$497,378,899,763,526,240,000.00$9,013$1,875.40+$497657939618196.94MGGSM
6$887,590,576,640,622,200,000,000$887,058,082,645,230,600,000,000.00$10,306$2,680.72+$887590576640622208.00MGGSM
7$1,479,547,418,610,237,200,000,000,000$1,478,597,696,693,231,600,000,000,000.00$12,820$4,101.38+$1.4795474186102372e+21MGGSM
8$2,305,052,548,351,757,200,000,000,000,000$2,303,469,432,613,844,500,000,000,000,000.00$17,673$6,826.70+$2.3050525483517572e+24MGGSM
9$3,356,370,330,330,650,300,000,000,000,000,000$3,353,903,924,103,914,000,000,000,000,000,000.00$27,543$12,591.86+$3.3563703303306504e+27MGGSM
10$4,567,699,004,441,311,000,000,000,000,000,000,000$4,564,107,688,187,857,300,000,000,000,000,000,000.00$49,560$26,258.71+$4.567699004441311e+30MGGSM

GGSM vs PFE: Complete Analysis 2026

GGSMStock

Gold and GemStone Mining Inc. focuses on the acquisition, exploration, and development of gold and silver properties in North and South America. It has a collaboration agreement with Ridgeback Mining (Sierra Leone) Limited regarding a joint venture on three diamond and gold properties in Sierra Leone. The company holds mining claims in British Columbia, Canada and Sinaloa, Mexico for gold and rare earth metals. It also has 100% interest in the Gringo Viejo Project that consists of 3,202 hectares and is located on the best gold zone, Mexico. The company was formerly known as Global GSM Solutions, Inc. and changed its name to Gold and GemStone Mining Inc. in April 2012. Gold and GemStone Mining Inc. was founded in 2008 and is based in Irving, Texas.

Full GGSM Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this GGSM vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GGSM vs SCHDGGSM vs JEPIGGSM vs OGGSM vs KOGGSM vs MAINGGSM vs JNJGGSM vs MRKGGSM vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.